Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

IGC Pharma (IGC) Other Gross PP&E Adjustments (2016 - 2025)

IGC Pharma has reported Other Gross PP&E Adjustments over the past 14 years, most recently at $3.9 million for Q3 2025.

  • Quarterly Other Gross PP&E Adjustments fell 34.34% to $3.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Sep 2025, down 34.34% year-over-year, with the annual reading at $5.8 million for FY2025, 2.09% down from the prior year.
  • Other Gross PP&E Adjustments was $3.9 million for Q3 2025 at IGC Pharma, down from $5.9 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $13.3 million in Q4 2021 and troughed at $3.9 million in Q3 2025.
  • The 5-year median for Other Gross PP&E Adjustments is $9.8 million (2023), against an average of $9.1 million.
  • Year-over-year, Other Gross PP&E Adjustments increased 13.35% in 2021 and then crashed 40.24% in 2024.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $13.3 million in 2021, then decreased by 26.98% to $9.7 million in 2022, then fell by 24.35% to $7.4 million in 2023, then dropped by 21.01% to $5.8 million in 2024, then tumbled by 33.45% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Other Gross PP&E Adjustments are $3.9 million (Q3 2025), $5.9 million (Q2 2025), and $5.8 million (Q1 2025).